Metabomed Overview

  • Founded
  • 2013
  • Status
  • Private
  • Employees
  • 10
  • Latest Deal Type
  • Series B
  • Latest Deal Amount
  • $12.5M
Latest Deal Amount
  • Investors
  • 7

Metabomed General Information


Operator of a drug discovery company intended to assist in the field of cancer metabolism. The company's proprietary target identification platform is based on computational biology, genomics, and metabolomics and identifies the metabolic pathways that arise uniquely in cancers that enable and support their growth and thereby develop small molecules that specifically target the reprogrammed cancer cells' metabolism to halt their growth, enabling oncologists to treat cancer growth while limiting damage to surrounding healthy tissues.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Other Healthcare Technology Systems
Primary Office
  • 18 HaKishon Street
  • Yavne 81220
  • Israel
+972 00-000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Metabomed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series B) 19-Dec-2019 $12.5M 000.00 000.00 Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 04-Apr-2016 0000 0000 000.00 Completed Startup
1. Seed Round 28-Nov-2013 $5M $5M 00.000 Completed Startup
To view Metabomed’s complete valuation and funding history, request access »

Metabomed Executive Team (11)

Name Title Board Seat Contact Info
Aviv Sagi Chief Financial Officer
Andreas Goutopoulos Ph.D Chief Scientific Officer
Eytan Ruppin Co-Founder & Scientific Advisor
Tomer Shlomi Co-Founder & Scientific Advisor
Philippe Nakache Ph.D Vice President, Chemistry
You’re viewing 5 of 11 executive team members. Get the full list »

Metabomed Board Members (10)

Name Representing Role Since
Daguang Wang Ph.D Yonjin Venture Board Member 000 0000
David Aviezer Ph.D Self Chairman 000 0000
Denis Patrick Ph.D Self Board Member 000 0000
Eyal Gottlieb Ph.D Self Co-Founder, Scientific Advisor & Board Member 000 0000
Ilka Wicke Ph.D Boehringer Ingelheim Venture Fund Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Metabomed Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Metabomed Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Yonjin Venture Corporate Venture Capital Minority 000 0000 000000 0
Arkin Holdings PE/Buyout Minority 000 0000 000000 0
Pfizer Ventures Corporate Venture Capital Minority 000 0000 000000 0
Boehringer Ingelheim Venture Fund Corporate Venture Capital Minority 000 0000 000000 0
M Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »